Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
Vaccines|February 24, 2024
Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational StudyAdeep Puri, Andrew J Pollard, Catherine Schmidt-Mutter, et al.
Viruses|April 26, 2025
Assessment of Relative Contributions of Lifestyle, Behavioral and Biological Risk Factors for Cervical Human Papillomavirus Infections in Female Sex WorkersImran Morhason-Bello, Kyeezu Kim, Yusuf Bello, et al.
Frontiers in Global Women'S Health|December 20, 2024
Pregnancy and neonatal outcomes in Eastern Democratic Republic of the Congo: a systematic reviewKambale Kasonia, Hannah Brindle, Daniela Manno, et al.
The Lancet. Global Health|September 16, 2022
Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trialKathy Baisley, Troy J Kemp, Aimée R Kreimer, et al.
PLOS Global Public Health|May 2, 2025
Using an analogue-digital hybrid clinical data management platform during a two-dose preventive Ebola virus vaccine trial in Goma, the Democratic Republic of the CongoHannah E Brindle, Darius Tetsa-Tata, Tansy Edwards, et al.
BMJ Open|March 9, 2022
Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the CongoDeborah Watson-Jones, Hugo Kavunga-Membo, Rebecca F Grais, et al.
NPJ Vaccines|November 28, 2025
Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trialRebecca Wiggins, Kathy J Baisley, Jackton Indangasi, et al.
Tropical Medicine & International Health : TM & IH|April 3, 2025
Regulator experiences of trials during Ebola epidemics in Sierra Leone, Guinea, and the Democratic Republic of the CongoKambale Kasonia, Frank Baiden, Frédéric Le Marcis, et al.
Emerging Microbes & Infections|November 19, 2024
Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trialSimon Valayer, Marie Alexandre, Mélanie Prague, et al.
The Lancet. Global Health|February 16, 2024
Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trialsKathy Baisley, Troy J Kemp, Nelly R Mugo, et al.
Pageof 15